Coloplast A/S
Other OTCRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Coloplast A/S is a Danish multinational company specializing in the development, manufacture, and sale of medical devices and services primarily in the fields of ostomy care, continence care, wound and skin care, interventional urology, and feminine care. The company offers a comprehensive product portfolio including ostomy systems and accessories under brands like SenSura® Mio; continence care products such as intermittent catheters and external urine collectors; advanced wound dressings including Biatain® Silicone Fit; bowel care solutions like Peristeen®; and voice and respiratory care products following its acquisition of Atos Medical. Coloplast operates globally with sales in over 50 countries and employs more than 12,000 people. Founded in 1957 and headquartered in Humlebæk, Denmark, it serves hospitals, clinics, and direct consumers. In recent major developments, Coloplast launched the Impact4 strategy in 2025, outlining a five-year plan focused on accelerating organic revenue growth, improving profitability, and strengthening market leadership in chronic care segments. Key strategic priorities include expanding its ostomy care portfolio with innovations such as the digital leakage notification system Heylo™ and new variants in the SenSura Mio range, including a black color option and Convex Soft with Flex coupling. The company is also advancing growth in interventional urology with new product introductions and enhancement of women's health offerings through products like Intibia™, targeting FDA approval for a 2026/27 launch. Operationally, Coloplast is enhancing global operations for improved margins and cash flow, emphasizing innovation leadership by integrating advanced wound care technologies via acquisitions like Kerecis. Recent adjustments in the executive leadership team support these strategic initiatives. Coloplast’s industry segments focus on intimate healthcare needs, targeting patients with chronic conditions requiring sensitive, user-centric medical solutions. Its geographic footprint spans Europe, North America, and emerging markets, with an increased emphasis on direct-to-consumer digital engagement. The company continues to invest in product innovation, regulatory pathways, and expansion through bolt-on acquisitions. Its long-term financial targets include high single-digit organic revenue growth and an EBIT margin expansion toward or above current levels, ensuring sustained value creation for customers and shareholders.
Coloplast: Went 'BUY' A Bit Early
Coloplast A/S (CLPBY) Q2 2026 Earnings Call Transcript
Coloplast A/S (CLPBY) Q4 2026 Guidance Call Transcript
Comparing Coloplast A/S (OTCMKTS:CLPBY) & Bluejay Diagnostics (NASDAQ:BJDX)
Coloplast: The Market Is Throwing Away A High-Quality Compounder
Coloplast A/S - Trading in Coloplast shares by board members, executives or associated persons
Coloplast A/S - Trading in Coloplast shares by board members, executives or associated persons
Coloplast appoints Gavin Wood as new CEO
CLPBY or PEN: Which Is the Better Value Stock Right Now?
Reviewing OPKO Health (NASDAQ:OPK) and Coloplast A/S (OTCMKTS:CLPBY)
Coloplast A/S - Updated Financial Calendar 2025-26
Coloplast A/S (OTCMKTS:CLPBY) Shares Gap Down – What’s Next?
Coloplast A/S (CLPBY) Q1 2026 Earnings Call Transcript
Coloplast A/S - Interim Financial Report, Q1 2025/26
Coloplast A/S - Interim Financial Report, Q1 2025/26
CLPBY vs. PEN: Which Stock Is the Better Value Option?
Coloplast announces changes to Executive Leadership Team
Coloplast A/S (CLPBY) Shareholder/Analyst Call Transcript
Coloplast A/S - Decisions at the Annual General Meeting 2025
Coloplast A/S (CLPBY) Q4 2025 Earnings Call Transcript